seekingalpha.com · 6 jul

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks.

seekingalpha.com · 12 jun

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript

benzinga.com · 12 jun

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ongoing open-label extension study of once-weekly canvuparatide in adults with chronic hypoparathyroidism.

globenewswire.com · 12 jun

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

globenewswire.com · 1 jun

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an investor webcast and conference call at 8:00 am ET on Friday, June 12, 2026 to discuss presentations for once-weekly canvuparatide at the upcoming Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.

fool.com · 27 may

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.

globenewswire.com · 26 may

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass.

seekingalpha.com · 14 may

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript